Clinical Trial Update: Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and expansion study evaluating ODC-IL2 in adults with advanced or metastatic solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ODC-IL2

Snippet

Sponsor: Trutino Biosciences Inc. | Conditions: Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Status: RECRUITING